Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

Phase 1

Active, not recruiting

• Conditions: Type 2 Diabetes Mellitus
• Interventions: Drug: BMF-219

• Registration Number: NCT05731544
• Lead Sponsor: Biomea Fusion Inc.

Brief Summary

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.

Detailed Description

This is a Phase 1/ 2 study that will examine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple dose levels of BMF-219, an orally bioavailable selective covalent inhibitor of menin, in healthy subjects and in subjects with T2D. This study will assess the effect of BMF-219 as single ascending dose (SAD) and multiple ascending dose (MAD), Expansion Cohort will explore 100mg and 200mg dose levels.

Study Timeline

• Study Start: 2022-08-17
• Study First Submitted: 2022-12-26
• Study First Submitted QC: 2023-02-07
• Study First Posted: 2023-02-16
• Primary Completion: 2024-11-18
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-13
• Last Update Posted: 2025-02-14
• Study Completion: 2025-05

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 414

Inclusion Criteria

Healthy Subject Inclusion Criteria:

1. Males or females, age ≥18 and ≤65 years.

2. BMI ≥18 and ≤35 kg/m2.

3. Subjects are healthy on the basis of their medical history, physical examination, ECG, and routine laboratory data.

4. All subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.

Subjects with T2D: (MAD Cohorts) Inclusion Criteria:

1. Males or females, age ≥18 and ≤65 years.
2. Diagnosed with T2D within the last 15 years.
3. Treated with lifestyle management with or without at the most 3 anti-diabetic medications with a stable dose for at least 2 months prior to screening. If on metformin, the stable dose should be at least 500mg/day.
4. HbA1c ≥7.0% and ≤10.5%.
5. BMI ≥25 and ≤40 kg/m2.
6. Females are to be not pregnant, non-lactating.
7. All Subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.

Subjects with T2D: (Expansion Cohort) Inclusion Criteria:

1. Males or females, age ≥18 and ≤65 years.
2. Diagnosed with T2D within the last 7 years.
3. Treated with lifestyle management with or without at the most 3 anti-diabetic medications with a stable dose for at least 2 months prior to screening. If on metformin, the stable dose should be at least 500mg/day.
4. HbA1c ≥7.0% and ≤10.5%.
5. BMI ≥25 and ≤40 kg/m2.
6. Females are to be not pregnant, non-lactating.
7. All Subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.

Exclusion Criteria

Healthy Subject Exclusion Criteria:

1. Evidence or history of any clinically significant disease or malignancy.
2. Mean QTcF ≥ 440 msec on triplicate ECGs. Use of medications known to significantly prolong the QT or QTcF interval.
3. History of hypertension or untreated hypertension (sitting systolic blood pressure (BP) ≥140 and diastolic BP ≥90 mm Hg).
4. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
5. History of stomach or intestinal surgery or resection (except appendectomy, hernia repair, and/or cholecystectomy).
6. A history or evidence of HIV, HCV, or HBV infection at screening or active COVID-19 infection on screening.
7. Receiving an investigational intervention or having participated in another clinical trial within 30 days.
8. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.
9. Received prior menin inhibitor treatment.

Subjects with T2D (MAD Cohorts) Exclusion Criteria:

1. Type 1 Diabetes Mellitus or a secondary form of diabetes or any prior history of diabetic ketoacidosis.
2. Have had recurrence (≥2 episodes) of severe hypoglycemia (defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery) within the last 6 months prior to screening or, has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms as judged by the Investigator.
3. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
4. Use of anti-diabetes medications (sulfonylureas, insulin, dipeptidyl peptidase-IV inhibitor [DPP-4I] [linagliptin and saxagliptin only] thiazolidinediones) within last 2 months prior to screening.
5. Fasting plasma glucose ≥255 mg/dL, fasting C-peptide <0.8 ng/mL, fasting insulin >55 μIU/mL.
6. Mean QTcF ≥450 ms. Use of medications known to significantly prolong the QT or QTc interval.
7. Fasting triglyceride ≥500 mg/dL.
8. Have an eGFR <60 mL/min/1.73 Equation at screening.
9. AST or ALT > 1.5 × ULN, bilirubin > 1.5 × ULN. Isolated GGT elevation >2.5 ULN without > 1.5 x ULN AST, ALT and/or total bilirubin but with a history of abnormal LFTs in the last 6 months or a medical history of a liver disorder should be excluded.
10. History of acute or chronic pancreatitis and serum lipase and/or amylase above 1.5 x ULN.
11. Active HBV or active HCV at screening. Known positive test, if any, prior to screening or history of HIV. An active COVID-19 infection at screening.
12. TSH >6 mIU/L or <0.4 mIU/L (on stable thyroid replacement dose for 3 months prior to screening).
13. Severe uncontrolled treated or untreated hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg).
14. History of stomach or intestinal surgery or resection and/or gastroparesis (except that appendectomy, hernia repair, and/or cholecystectomy will be allowed).
15. History of cirrhosis.
16. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.

Subjects with T2D (Expansion Cohort) Exclusion Criteria:

1. Type 1 Diabetes Mellitus or a secondary form of diabetes.
2. Prior history of diabetic ketoacidosis or hyperosmolar coma.
3. History of severe hypoglycemia (defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery) within the last 6 months prior to screening or, has a history of hypoglycemia unawareness.
4. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1 (MEN1).
5. Use of any of the following anti-diabetes medications within 2 months prior to screening: sulfonylureas, insulin, and the dipeptidyl peptidase-4 inhibitors (DPP4i) linagliptin and saxagliptin (sitagliptin and other DPP4i allowed) thiazolidinones [TZD]) within last 2 months prior to screening.
6. Fasting plasma glucose ≥255 mg/dL, fasting C-peptide <0.8 ng/mL, fasting insulin >55 μIU/mL.
7. Mean QTcF interval >450 ms on triplicate ECGs. Use of prescription or over-the-counter medications known to significantly prolong the QT or QTc interval is excluded.
8. Fasting triglyceride ≥500 mg/dL.
9. eGFR<60 mL/min/1.73.
10. AST or ALT >1.5 × ULN, Total bilirubin >1.5 × ULN at screening.
11. History of acute or chronic pancreatitis and serum lipase and/or amylase above 1.5 x ULN.
12. Active HBV or active HCV at screening. Known positive test or history of HIV. An active COVID-19 infection at screening.
13. TSH >6 mIU/L or <0.4 mIU/L (on stable thyroid replacement dose for 3 months prior to screening).
14. Severe uncontrolled treated or untreated hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg).
15. History of stomach or intestinal surgery or resection and/or gastroparesis.
16. History of cirrhosis.
17. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Phase 2 Expansion Cohort	BMF-219	Phase 2 Expansion Cohort adults with T2D randomized 3:1 ratio receiving BMF-219 or placebo.
Phase 1 SAD Cohorts	BMF-219	Phase 1 SAD Cohorts with healthy adults randomized 3:1 receiving BMF-219 or placebo. A pair of sentinel subjects (randomly assigned 1 active drug and 1 placebo) will be dosed 48 hours prior to dosing of the remainder of subjects in each cohort.
Phase 1 single dose food effect sub-study	BMF-219	Phase 1 single dose food effect sub-study with healthy adults randomized 1:1:1:1:1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high fat meal.
Phase 1 single dose tablet PK sub-study	BMF-219	Phase 1 single dose x3 PK tablet open-label sub-study with healthy adults randomized 1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high-fat meal).
Phase 2 MAD Cohorts	BMF-219	Phase 2 MAD Cohorts with healthy adults (MAD 1, randomized 3:1) or adults with T2D (MAD 2-4 \& 6-8, randomized 5:1) receiving BMF-219 or placebo. MAD 5 is BMF-219 only.

Primary Outcome Measures

Name	Time	Method
Safety Assessments	52 weeks	Assessed by treatment emergent adverse events. (TEAEs), drug discontinuation due to TEAEs, serious adverse events, clinically significant laboratory, vital, and ECG evaluations.
Pharmacokinetics Assessments	12 weeks	Assessed by effect of fed conditions on serial and sparse pharmacokinetic data.
Change in HbA1c	26 weeks	Assess the change in HbA1c from baseline to week 26.

Secondary Outcome Measures

Name	Time	Method
To assess the effect on HbA1c	26 Weeks	Proportion of subjects achieving an HbA1c \< 7% at Week 26.

Trial Locations

Locations (39)

David Kavtaradze MD, Inc; 🇺🇸 Cordele, Georgia, United States

Hope Clinical Research; 🇺🇸 Canoga Park, California, United States

Ark Clinical Research, LLC; 🇺🇸 Fountain Valley, California, United States

Velocity Clinical Research; 🇺🇸 Jordan, Utah, United States

Ark Clinical Research; 🇺🇸 Long Beach, California, United States

Catalina Research Institute, LLC; 🇺🇸 Montclair, California, United States

Metro Clinical Trials; 🇺🇸 San Bernardino, California, United States

CMR of Greater New Haven, LLC; 🇺🇸 Hamden, Connecticut, United States

Southwest General Healthcare Center; 🇺🇸 Fort Myers, Florida, United States

G+C Research Group; 🇺🇸 Hialeah, Florida, United States

Sunbright Health Research Centers; 🇺🇸 Homestead, Florida, United States

Diabetes Care Center; 🇺🇸 Hudson, Florida, United States

Panax Clinical Research; 🇺🇸 Miami Lakes, Florida, United States

Avantis Clinical Research; 🇺🇸 Miami, Florida, United States

Century Research LLC; 🇺🇸 Miami, Florida, United States

Entrust Clinical Research; 🇺🇸 Miami, Florida, United States

Omega Research Orlando; 🇺🇸 Orlando, Florida, United States

Privia Medical Group; 🇺🇸 Savannah, Georgia, United States

Cedar Crosse Research Center; 🇺🇸 Chicago, Illinois, United States

IMA Clinical Research St. Louis; 🇺🇸 Saint Louis, Missouri, United States

Santa Rosa Medical Centers of Nevada; 🇺🇸 Las Vegas, Nevada, United States

Omera Health; 🇺🇸 Brooklyn, New York, United States

IMA Clinical Research Manhattan; 🇺🇸 New York, New York, United States

Carolina Research Center; 🇺🇸 Shelby, North Carolina, United States

Wake Forest Health Network, LLC, Medical Plaza; 🇺🇸 Winston-Salem, North Carolina, United States

Diabetes and Endocrinology Associates of Stark County; 🇺🇸 Canton, Ohio, United States

Medical Care, LLC; 🇺🇸 Elizabethton, Tennessee, United States

IMA Clinical Research; 🇺🇸 Austin, Texas, United States

Zenos Clinical Research; 🇺🇸 Dallas, Texas, United States

Synergy Groups Medical LLC; 🇺🇸 Houston, Texas, United States

Synergy Group Medical; 🇺🇸 Missouri City, Texas, United States

Clinical Trials of Texas, LLC; 🇺🇸 San Antonio, Texas, United States

Diabetes & Glandular Disease Clinic, P.A.; 🇺🇸 San Antonio, Texas, United States

Simcare Medical Research; 🇺🇸 Sugar Land, Texas, United States

Manassas Clinical Research; 🇺🇸 Manassas, Virginia, United States

BC Diabetes; 🇨🇦 Vancouver, British Columbia, Canada

Centricity Research Brampton Endocrinology; 🇨🇦 Brampton, Ontario, Canada

Centricity Research LMC; 🇨🇦 Toronto, Ontario, Canada

BioPharma Services Inc.; 🇨🇦 Toronto, Canada